

RECEIPT
PCT

I hereby certify that this correspondence is being deposited with the United States Postal Services on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.


Date of Signature
and Deposit:

10/31/00

Attorney of Record



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicants: Peter J. Sims, et al.
Serial No.: 09/600,535
Filed: July 18, 2000
For: METHODS AND COMPOSITIONS TO ALTER
TISSUE SUSCEPTIBILITY TO IMMUNE
INJURY, TO PROGRAMMED CELL DEATH, AND
TO CLEARANCE BY THE
RETICULOENDOTHELIAL SYSTEM
Group Art Unit: 1646
Examiner: --

**Office of Initial Patent Examination's
Customer Service Center**

Commissioner for Patents
Washington, D.C. 20231

REQUEST FOR CORRECTED FILING RECEIPT

Dear Sir:

In the matter of the above-identified case, Applicants respectfully request a corrected Filing Receipt. The enclosed copy of the Filing Receipt received October 19, 2000 indicates that this application was filed on September 18, 2000. The application was actually filed on July 18, 2000.

No fees are believed necessary to correct the Filing Receipt. However, if fees are necessary please charge Deposit Account No. 17-0055.

Respectfully submitted,

Peter J. Sims, et al.

October 31, 2000

By: 

Jean C. Baker
QUARLES & BRADY LLP
411 East Wisconsin Avenue
Milwaukee, WI 53202
Reg. No.: 35,433
(414) 277-5709



UNITED STATES PATENT AND TRADEMARK OFFICE


COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	CLAIMS	IND CLAIMS
09/600,535	09/18/2000	1646	692	160180.90121	16	28	6

Jean C Baker
Quarles & Brady
411 East Wisconsin Ave Suite 2040
Milwaukee, WI 53202-4497

09/18/2000

FILING RECEIPT



OC000000005487317



Date Mailed: 10/19/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Peter J. Sims, Del Mar, CA ;
Therese Wiedmer, Del Mar, CA ;
Ji Zhao, Solana Beach, CA ;

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A 371 OF PCT/US99/01087 01/19/1999
WHICH CLAIMS BENEFIT OF 60/071,950 01/20/1998

Foreign Applications

If Required, Foreign Filing License Granted 10/19/2000

** SMALL ENTITY **

Title

Methods and compositions to alter tissue susceptibility to immune injury, to programmed cell death, and to clearance by the reticuloendothelial system

Preliminary Class

536

OCT 25 2000

Data entry by : NGUYEN, SON

Team : OIPE

Date: 10/19/2000





**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

RECEIVED

FEB 09 2001

TECH CENTER 1800/2900

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231